CA9 and neoplasm: In this study, we evaluated the efficacy of CA IX and CA XII selective inhibitor SLC-0111, an ureido-substituted benzenesulfonamide small molecule, to sensitize HNSCC cells and animal models to Cis-Pt, thus reducing tumor cell growth and dissemination.